A Single Arm, Open Label, Single-center Dose-exploratory Clinical Study of Linperlisib in Combination With EZH2 Inhibitor SHR2554 in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.

开始日期2024-12-01

申办/合作机构-

NCT06679673

/ Not yet recruiting临床2期IIT

An Explorative Study of SHR-1701 Combined with SHR2554 and BP102(bevacizumab) for Metastatic Colorectal Cancer.

Response to oncologic treatment in mCRC is currently limited.

开始日期2024-12-01

申办/合作机构

复旦大学

NCT06568094

/ Recruiting临床1/2期

An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

开始日期2024-09-06

申办/合作机构

江苏恒瑞医药股份有限公司

100 项与 Zeprumetostat 相关的临床结果

登录后查看更多信息

100 项与 Zeprumetostat 相关的转化医学

登录后查看更多信息

100 项与 Zeprumetostat 相关的专利（医药）

登录后查看更多信息

项与 Zeprumetostat 相关的文献（医药）

2024-04-01·Clinical cancer research : an official journal of the American Association for Cancer Research

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Article

作者: Qi, Junyuan ; Su, Hang ; Cai, Zhen ; Huang, Yanhua ; Zuo, Xuelan ; Li, Kunyan ; Li, Yijing ; Wu, Jianyuan ; He, Chuan ; Zhou, Hui ; Hao, Siguo ; Liu, Yanyan ; Li, Lanfang ; Li, Zhi-Ming ; Xiao, Zhenyu ; Zhu, Jun ; Li, Zengjun ; Jin, Zhengming ; Li, Dengju ; Song, Yuqin ; Wu, Meng ; Shen, Jie ; Sun, Xiuhua

Abstract:

Purpose::

Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and the prognosis is extremely poor. SHR2554 is an oral inhibitor against EZH2, a rational therapeutic target for lymphomas.

Patients and Methods::

This was a multicenter, two-part, phase I study of SHR2554 in r/r mature lymphoid neoplasms. In part I, 350 mg twice daily was established as the recommended phase II dose (RP2D) based on the findings during dose escalation and expansion; subsequently, selected lymphoma subtypes were recruited in clinical expansion cohorts to receive SHR2554 at RP2D. Here, we provide an in-depth assessment of SHR2554 at RP2D in subpopulation with r/r PTCL.

Results::

Twenty-eight patients were included for analysis (17 angioimmunoblastic T-cell lymphoma and 11 not otherwise specified). Eighteen (64%) patients had received ≥2 lines of previous anticancer therapies. The objective response rate was 61% [95% confidence interval (CI), 41–78]. Responses were still ongoing in 59% (10/17) of the responders; estimated median duration of response was 12.3 months (95% CI, 7.4–not reached). Median progression-free survival was 11.1 months (95% CI, 5.3–22.0), and 12-month overall survival rate was 92% (95% CI, 72–98). The most common grade 3 or 4 treatment-related adverse events were decreased platelet count [nine (32%)] as well as decreased white blood cell count, decreased neutrophil count, and anemia [four (14%) for each]. No treatment-related deaths were reported.

Conclusions::

This extended follow-up analysis further supports SHR2554 as a therapeutic opportunity for patients with r/r PTCL.

2023-01-01·Cancer medicine

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial

Article

作者: Yang, Guoping ; Yang, Xiaoyan ; Huang, Jie ; Xiang, Yuxia ; Zou, Chan ; Wang, Hong ; Yang, Shuang ; Cui, Chang ; Zou, Yi ; Deng, Kunhong

Abstract:

Background:

SHR2554, a novel oral Enhancer of Zeste Homolog 2 inhibitor, shows broad‐spectrum anti‐tumor efficacy in preclinical studies. As SHR2554 is mainly metabolized by CYP3A4, it is helpful to conduct research on the effects of itraconazole, a strong inhibitor of CYP3A4‐metabolizing enzymes, on the pharmacokinetic characteristics and safety of SHR2554.

Methods:

We conducted a single‐center, open‐label pharmacokinetic study of itraconazole on SHR2554 in 18 healthy Chinese subjects. Subjects were orally administrated SHR2554 50 mg on Day 1, itraconazole 200 mg Quaque Die (QD) from Days 4 to 7, SHR2554 50 mg co‐administrated with itraconazole 200 mg on Day 8, and itraconazole 200 mg QD from Days 9 to 12. Then, 4 ml of venous blood was collected at predetermined time points. Plasma SHR2554 concentrations were analyzed using a validated high‐performance liquid chromatography tandem mass spectrometry method. Pharmacokinetic parameters were calculated using Phoenix WinNonlin v8.1.

Results:

The Cmax of SHR2554 alone and in combination was 10.197 ± 7.0262 ng·ml−1 versus 70.538 ± 25.0219 ng·ml−1, AUC0–∞ was 50.99 ± 19.358 h·ng·ml−1 versus 641.53 ± 319.538 h·ng·ml−1, and AUC0–t was 28.70 ± 18.913 h·ng·ml−1 versus 612.13 ± 315.720 h·ng·ml−1. Co‐administration of SHR2554 and itraconazole caused 7.73‐, 12.47‐, and 23.75‐fold adjusted geometric mean ratios increases in SHR2554 Cmax, AUC0−∞ and AUC0−t respectively. The co‐administration regimen was well tolerated and had a good safety profile.

Conclusions:

Compared with a single dose of SHR2554 50 mg, the exposure of SHR2554 in vivo was significantly affected by the combined administration of itraconazole.

2022-07-01·Lancet Haematology

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Article

作者: He, Chuan ; Cai, Zhen ; Qi, Junyuan ; Su, Hang ; Li, Kunyan ; Zhang, Xiaojing ; Wang, Weiwei ; Zhou, Hui ; Jin, Zhengming ; Li, Zhi-Ming ; Li, Yijing ; Li, Lanfang ; Hao, Siguo ; Wu, Jianyuan ; Zuo, Xuelan ; Song, Yuqin ; Zhu, Jun ; Zou, Jianjun ; Liu, Yanyan ; Zhou, Jianfeng

BACKGROUND:

Dysregulation of EZH2 has a crucial role in lymphomagenesis. We did a first-in-human study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of SHR2554, an oral EZH2 inhibitor, in patients with relapsed or refractory mature lymphoid neoplasms, including B-cell lymphomas, T-cell lymphomas, and classical Hodgkin lymphoma.

METHODS:

This was a multicentre, dose-escalation, dose-expansion, and clinical expansion phase 1 study done at 13 hospitals in China. Eligible patients had histologically or cytologically confirmed mature lymphoid neoplasms that had relapsed or were refractory to standard systemic therapies or had no standard-of-care. The study included a dose-escalation phase, at doses of SHR2554 from 50 mg to 800 mg twice daily; a dose-expansion phase, at two selected doses; and a subsequent clinical expansion phase at the recommended phase 2 dose in selected tumours. Primary endpoints were the safety, maximum tolerated dose, and recommended phase 2 dose. Objective response rate was a secondary endpoint. Safety and activity were assessed in all patients who received at least one dose of SHR2554 and had at least one post-baseline evaluation. This study is registered with ClinicalTrials.gov, NCT03603951, and follow-up is ongoing.

FINDINGS:

Between Aug 14, 2018, and July 13, 2021, 113 patients received SHR2554. At data cutoff (Sept 10, 2021), the median follow-up duration was 7·0 months (IQR 3·7-12·0). 71 (63%) patients were men and 42 (37%) were women, 110 (97%) were of Han ethnicity and 3 (3%) of other ethnicities, and 53 (47%) had received three or more lines of previous anticancer therapies. Dose-limiting toxicities occurred in two (67%) of three patients who received 400 mg SHR2554 twice daily and one (17%) of six patients who received 350 mg SHR2554 twice daily. The maximum tolerated dose and recommended phase 2 dose was determined to be 350 mg twice daily. The most common grade 3 or 4 treatment-related adverse events in all 113 patients were decreased platelet count (20 [18%]), decreased neutrophil count (ten [9%]), decreased white blood cell count (nine [8%]), and anaemia (seven [6%]). 18 (16%) patients had serious treatment-related adverse events. Two patients (2%) died due to treatment-related adverse events: one (1%) due to skin infection and toxic epidermal necrolysis and one (1%) due to respiratory failure. 107 (95%) of the 113 enrolled patients had post-baseline assessments for tumour response and were included in the activity analysis. 46 (43%; 95% CI 33-53) of these 107 patients had an overall response.

INTERPRETATION:

SHR2554 showed an acceptable safety proﬁle and promising antitumour activity in patients with relapsed or refractory lymphomas, providing evidence for future investigations.

FUNDING:

Jiangsu Hengrui Pharmaceuticals.

TRANSLATION:

For the Chinese translation of the abstract see Supplementary Materials section.

110

项与 Zeprumetostat 相关的新闻（医药）

2025-06-03

·恒瑞医药

2025 EHA抢先看丨恒瑞创新药海曲泊帕、SHR2554等14项研究成果将发布

2025年欧洲血液学协会年会（EHA 2025）将于6月12日至15日在意大利米兰举行，作为全球血液学领域最具影响力的学术平台之一，EHA每年都吸引着来自世界各地的专家学者，共同分享并探讨有关血液学的创新理念及最新的科学与临床研究成果。截至发稿日，恒瑞医药自主研发的1类创新药TPO受体激动剂海曲泊帕（恒曲®）、新型选择性口服EZH2抑制剂SHR2554、靶向VEGFR2小分子酪氨酸激酶抑制剂甲磺酸阿帕替尼片（艾坦®）以及合作引进1类创新药PI3Kδ抑制剂林普利塞（因他瑞®）共14项研究入围1本次大会，其中1项研究入选口头（Oral）报告，8项研究壁报展示（Poster），5项研究线上发表（Publication Only）。本文特做梳理，带大家先睹为快！1.摘要号：S246（Oral）●EZH2抑制剂SHR2554治疗复发或难治性（R/R）外周T细胞淋巴瘤（PTCL）的关键性研究A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 （EZH2）, in relapsed or refractory （R/R） peripheral t-cell lymphoma （PTCL）第一作者：宋玉琴北京大学肿瘤医院通讯作者：朱军北京大学肿瘤医院关键信息：SHR2554是一种口服、高选择性小分子EZH2抑制剂，对野生型和突变型EZH2均表现出抑制性。临床前研究表明2SHR2554可竞争性结合EZH2的催化SET结构域，抑制其甲基转移酶活性，降低H3K27甲基化水平，从而诱导G1细胞周期阻滞、细胞凋亡，并最终抑制淋巴瘤细胞的增殖和小鼠淋巴瘤移植瘤的生长。本次EHA报告了一项关于SHR2554治疗R/R PTCL患者的关键单臂研究的结果（NCT03603951）。本研究已达到其主要终点，SHR2554在R/R PTCL患者中表现出具有前景的有效性且安全性可控，有望成为这一具有治疗挑战性人群新的治疗选择。2.摘要号：PS1651●海曲泊帕联合环孢素A作为非重型再生障碍性贫血患者的一线治疗：一项多中心、随机、双盲、安慰剂对照II期临床研究Hetrombopag Combined with Cyclosporine A as First-line Treatment in Patients with Non-Severe Aplastic Anemia: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase II Study第一作者：赵馨中国医学科学院血液学研究所通讯作者：张凤奎中国医学科学院血液学研究所3.摘要号：PF669●海曲泊帕联合环孢素一线治疗非重型再生障碍性贫血患者：一项2期多中心临床研究Adding Hetrombopag to Cyclosporine for First-line Treatment of Patients With Non-severe Aplastic Anemia: a Phase-2 Multi-center-clinical Study第一作者：张乐乐中国医学科学院血液学研究所通讯作者：施均中国医学科学院血液学研究所4.摘要号：PS1656●环磷酰胺联合标准免疫抑制治疗可改善重型再生障碍性贫血的早期缓解率：一项II期临床研究Cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia: a phase ii clinical trial第一作者：潘虹中国医学科学院血液学研究所通讯作者：施均中国医学科学院血液学研究所5.摘要号：PS1660●海曲泊帕与艾曲泊帕分别联合抗胸腺细胞球蛋白和环孢素A一线治疗重型再生障碍性贫血的疗效和安全性对比Comparison of of hetrombopag versus eltrombopag combined with anti-thymocyte globulin and cyclosporine a as first-line therapy for severe aplastic anemia: similar efficacy and safety第一作者：孙京男吉林大学第一医院通讯作者：何广胜江苏省人民医院6.摘要号：PB2809●改善肝炎相关再生障碍性贫血（HAAA）的预后：血小板生成素受体激动剂作为标准免疫抑制治疗辅助手段的作用Enhancing outcomes in hepatitis-associated aplastic anemia: the role of thrombopoietin receptor agonists as an adjunct to standard immunosuppressive therapy第一作者：王敏中国医学科学院血液学研究所通讯作者：葛美丽中国医学科学院血液学研究所7.摘要号：PF1253●TPO-RA联合西罗莫司治疗复发/难治性原发免疫性血小板减少症（ITP）有效：一项前瞻性单臂临床研究TPO-RA Combined With Sirolimus is Effective in the Treatment of Relapsed Immune Thrombocytopenia（ITP）: a Prospective, Single-arm Clinical Study第一作者：冯一梅陆军军医大学第二附属医院（新桥医院）通讯作者：张曦陆军军医大学第二附属医院（新桥医院）8.摘要号：PB3678●海曲泊帕联合大剂量地塞米松治疗初诊的ITP患者的有效性及安全性探索:一项多中心、单臂、前瞻性临床研究Efficacy and Safety of Hetrombopag Combined with High-Dose Dexamethasone as First-Line Therapy for Newly Diagnosed Primary Immune Thrombocytopenia: A Multicenter, Single-Arm Prospective Study第一作者：朱化超西安交通大学第一附属医院通讯作者：贺鹏程西安交通大学第一附属医院9.摘要号：PS2247●海曲泊帕用于治疗PARP抑制剂导致的血小板减少症的疗效和安全性：一项开放标签、前瞻性、II期临床试验Efficacy and Safety of Hetrombopag for PARP Inhibitor-Induced Thrombocytopenia: A Phase II Open-Label, Prospective Trial第一作者：郭勤浩复旦大学附属肿瘤医院通讯作者：居杏珠复旦大学附属肿瘤医院10.摘要号：PS2268●血小板生成素及血小板生成素受体激动剂对血小板活化和血栓形成的影响Effects of thrombopoietin and thrombopoietin receptor agonists on platelet activation and thrombosis第一作者：周凡昆明医科大学第二附属医院通讯作者：周泽平昆明医科大学第二附属医院11.摘要号：PS1941●林普利塞联合CHOP序贯自体造血干细胞移植后林普利塞单药维持治疗初治淋巴结T滤泡辅助细胞淋巴瘤（nTFHL）的前瞻性研究Linperlisib combined with chemotherapy followed by autologous stem cell transplantation and linperlisib maintenance in patients with newly diagnosed nodal T follicular helper cell lymphoma: interim analysis of a phase ii triall第一作者：刘卫平北京大学肿瘤医院通讯作者：朱军、宋玉琴北京大学肿瘤医院12.摘要号：PB2973●抗BCMA/GPRC5D双特异性CAR-T细胞疗法联合阿帕替尼桥接治疗伴髓外病变的复发/难治性多发性骨髓瘤：一项单臂、单中心1期试验BCMA/GPRC5D bispecific CAR T-cell therapy following apatinib bridging treatment in relapsed/refractory multiple myeloma with extramedullary disease: a single-arm, single-center phase 1 trial第一作者：邱玲西部战区总医院通讯作者：范方毅西部战区总医院13.摘要号：PB3278●林普利塞联合阿扎胞苷治疗外周T细胞淋巴瘤的疗效和安全性研究Efficacy and safety study of linperlisib combined with azacitidine in the treatment of peripheral T-cell lymphoma作者：邢宏运西南医科大学附属医院14.摘要号：PB3711●海曲泊帕乙醇胺片治疗携带新突变的MYH9综合征：1 例报告Treatment of MYH9 syndrome with newly developed mutations using herombopag olamine tablets:a case report第一作者：谭砚清安徽医科大学通讯作者：周莉安徽医科大学第二附属医院参考来源：1.https://library.ehaweb.org/eha/#!*menu=6*browseby=3*sortby=2*ce_id=2882.2.SHR2554片研究者手册.声明：1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。2.恒瑞医药不对任何药品和/或适应症作推荐。3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。撰稿：肿瘤中央医学事务部排版：程梦真责编：李玉莹往期精选| 研发创新 |恒瑞创新药、中国首恒瑞创新药瑞坦宁®获批，用于预防成人高度致吐性化疗引起的急性和迟发性恶心呕吐| 国际化 |恒瑞医药再次与德国默克集团达成合作，推进辅助生殖领域口服GnRH拮抗剂商业化落地恒瑞医药与默沙东就Lp(a)抑制剂HRS-5346签订独家许可协议| 重磅奖项 |喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！| 社会公益 |“健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

临床2期申请上市

2025-05-20

·CPHI制药在线

国产势力崛起：信诺维、恒瑞医药等如何领跑EZH2抑制剂全球竞速？

关注并星标CPHI制药在线5月19日，苏州信诺维医药科技股份有限公司的1类新药XNW5004片被CDE拟纳入突破性治疗品种，拟用于治疗既往接受过至少3线全身系统治疗的复发或难治性滤泡性淋巴瘤（EZH2野生型）。 XNW5004是信诺维医药自主研发的一种底物竞争性、选择性小分子EZH2抑制剂，在临床前体外、体内多个实体瘤模型上展示出良好的抗肿瘤活性，且安全性较好。 XNW5004被开发用于治疗外周T细胞淋巴瘤等淋巴瘤和前列腺癌等晚期或转移性实体瘤，其中复发或难治性外周 T 细胞淋巴瘤（PTCL）适应症于2024年9月被CDE授予突破性疗法认定。目前，XNW5004对照西达本胺治疗复发或难治性PTCL的随机、双盲、多中心III期临床试验正在进行中。针对前列腺癌，临床数据显示XNW5004联合恩扎卢胺可显著延长患者的无进展生存期（PFS）。此次XNW5004的复发或难治性滤泡性淋巴瘤适应症被CDE授予突破性治疗认定，将加速该适应症的开发进程。而已公布的XNW5004治疗复发或难治性非霍奇金淋巴瘤（NHL）的1期临床试验结果显示：XNW5004针对EZH2野生型滤泡性淋巴瘤患者的ORR为40%，DCR为100%，中位PFS和中位DOR均未达到。 EZH2抑制剂进展，SHR2554已报产，系首款国产创新 EZH2是目前非常热门的表观遗传学靶点之一，其是多梳抑制复合物2（PRC2）的催化活性亚单位，主要通过甲基化组蛋白H3第27位赖氨酸（H3K27me3）来抑制靶基因的转录，参与调控细胞周期、细胞衰老、细胞分化及肿瘤发生等病理生理过程。 EZH2最早发现在激素难治性转移性前列腺癌中高表达，后来发现其在乳腺癌、胃癌、结直肠癌、非霍奇金淋巴瘤等多种肿瘤中高表达，且其高表达与这些肿瘤的不良预后和肿瘤侵袭性相关。在血液肿瘤中，研究发现EZH2可通过抑制抑癌基因的表达与转录来对血液肿瘤的增殖和侵袭转移产生影响。而且，EZH2还可影响肿瘤免疫，其一方面可对CD4+、CD8+T及NK细胞的分化产生影响，同时调控调节性T细胞（Tregs）的功能表型；另一方面，研究显示EZH2对肿瘤微环境的抑制和重塑具有多重效应，通过抑制EZH2的表达，可以促进CD8+T细胞的功能并向肿瘤微环境转移，还可减轻Tregs对肿瘤微环境的影响，增加肿瘤微环境中抗原的表达、处理和呈递。据不完全统计，目前全球监管机构已批准2款EZH2抑制剂，即第一三共的伐美妥司他（Valemetostat，Ezharmia）和Epizyme/和黄医药的他泽司他（Tazemetostat，Tazverik）。其中伐美妥司他是全球首款获批的EZH1/2双重抑制剂,在日本获批治疗复发或难治性成人T细胞白血病/淋巴瘤 (ATL)和复发或难治性成人PTCL。他泽司他是全球首款获批的EZH2抑制剂，在美国获批多个适应症：16岁及以上不能完全切除的转移性或局部晚期上皮样肉瘤；至少接受两次全身治疗、EZH2突变阳性的成人复发或难治性FL；没有令人满意的替代治疗方案的成人R/R FL。2025年3月，他泽司他在国内获批，用于治疗复发或难治性FL。此外，目前全球还有多款在研EZH2抑制剂。恒瑞医药开发的EZH2抑制剂SHR2554进展较快，其治疗既往接受过至少1线系统性治疗的复发或难治PTCL的适应症上市申请正在国内接受优先审查。 SHR2554是一款新型、高效、选择性口服EZH2抑制剂，可选择性强效抑制野生型和突变型EZH2酶活性。已公布的首个人体临床试验结果显示，SHR2554每天2次350mg给药安全性可接受，对复发难治FL、PTCL和经典霍奇金淋巴瘤均显示出良好的抗肿瘤活性。而针对复发或难治PTCL，已公布的SHR2554针对复发/难治成熟淋巴瘤的1期临床研究中复发/难治性外周T细胞淋巴瘤（PTCL）部分的分析结果显示：在17例患者中ORR达61%，估计的mDOR为12.3个月，mPFS为11.1个月，12个月总生存率为92%。辉瑞的PF-06821497（mevrometostat）进展也较快，目前正在开展两项3期临床试验MEVPRO-1和MEVPRO-2，其中MEVPRO-1旨在评估PF-06821497联合恩扎卢胺对比恩扎卢胺或多西他赛治疗既往接受过醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌疗效和安全性，MEVPRO-2研究旨在评估PF-06821497联合恩扎卢胺治疗未经阿比特龙治疗的转移性去势抵抗性前列腺癌的疗效和安全性。已公布的1期临床试验结果显示，PF-06821497联合恩扎卢胺对经治转移性去势抵抗性前列腺癌（mCRPC）表现出可喜的抗癌活性，PF-06821497联合恩扎卢胺治疗既往经阿比特龙治疗的mCRPC的中位放射学无进展生存期（rPFS）为17.1个月，相比于历史数据（rPFS为4.8个月）有显著获益。海和药物的HH2853处于1/2期临床。该药是一款强效、高选择性EZH1/2小分子抑制剂。临床前研究显示：HH2853能强效抑制细胞内的整体H3K27me3水平，在PTCL、含有EZH2突变的弥漫性大B细胞淋巴瘤（DLBCL）以及含有SWI/SNF复合物亚基突变的多种实体瘤模型中均显示强效的体内外抗肿瘤活性，且同等剂量下HH2853的抗肿瘤活性与他泽司他相比更优。1期临床试验结果显示：HH2853具有良好的安全性和优异的药代动力学特征，在多瘤种中展示出初步疗效。中科拓苒的TR115、诺华的AXT1003等处于1期临床。其中TR115是一款新一代高活性高选择性EZH2抑制剂，细胞水平的研究结果显示其在表观遗传学靶点间具有良好的选择性，对EZH2野生型及EZH2 Y641F等突变均具有强烈的抑制作用。临床前研究结果显示：TR115能显著的抑制相关肿瘤细胞的增殖及肿瘤的生长，有望成为治疗非霍奇金性淋巴瘤和晚期恶性实体瘤等的新一代的靶向治疗药物。而AXT1003是一款EZH2靶向蛋白降解剂，其治疗晚期恶性肿瘤的1期临床试验正在进行中。总结作为表观遗传关键靶点，EZH2通过甲基化组蛋白H3K27调控基因转录，其异常表达与淋巴瘤、前列腺癌等多种肿瘤的恶性进展密切相关。目前全球已批准2款，恒瑞医药的SHR2554已经报产，辉瑞的PF-06821497和信诺维的XNW5004进展也相对较快，已进入3期临床。然而，目前EZH2抑制剂的发展仍有其局限性，适应症主要集中在淋巴瘤。未来，联合治疗（联合靶向药、化疗药等）、生物标志物开发（预测疗效与耐药）、新型抑制剂研发（克服耐药）以及拓展适应症（非肿瘤疾病领域）将成为EZH2研究的主要方向，有望为相关疾病治疗开辟新局面。END【企业推荐】智药研习社直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

突破性疗法临床1期ASH会议临床2期临床申请

2025-05-16

·ioncology

2025 EHA大会摘要公布！30项中国研究入选口头报告，于“时尚之都”米兰奏响中国最强音

编者按第30届欧洲血液学会年会（EHA 2025）将于6月12日至15日在意大利米兰盛大召开。作为全球血液学领域的顶尖学术盛会之一，本届大会将全面聚焦血液学及其各亚专科的最新进展，深入探讨循证诊疗新方法，发布临床与转化研究的重磅成果，呈现创新技术、精准诊断工具与风险评估策略的最新突破。日前，大会官网正式公布了本次年会的入选摘要（不含LBA）。《肿瘤瞭望-血液时讯》第一时间汇总整理了中国学者入选的口头报告名单（如有遗漏，欢迎留言补充），让我们一同见证东方智慧在“时尚之都”米兰的精彩绽放。全体大会摘要（Plenary Abstract Session）01摘要号：S102英文标题：BETTER SAFETY AND EFFICACY WITH ROPEGINTERFERON ALFA-2B OVER ANAGRELIDE AS SECOND-LINE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA IN THE TOPLINE RESULTS OF THE RANDOMIZED PHASE 3 SURPASS-ET TRIAL中文标题：随机Ⅲ期SURPASS-ET试验的初步结果显示，罗培干扰素α-2b相较阿那格雷二线治疗原发性血小板增多症的安全性和疗效更佳类型：口头报告专场名称：全体大会摘要汇报者及单位：Harry Gill，中国香港大学李嘉诚医学院口头报告（Oral Presentations）急性髓系白血病——生物学与转化研究Acute myeloid leukemia - Biology & translational research01摘要号：S134英文标题：DE NOVO DESIGN OF A CHROMATIN READER ZMYND8-TARGETING PEPTIDE PROTAC FOR ACUTE MYELOID LEUKEMIA THERAPY中文标题：靶向染色质识别蛋白ZMYND8的肽类PROTAC的重新设计：用于急性髓系白血病的治疗类型：口头报告专场名称：AML发病机制中的染色质和基因调控(Chromatin and gene regulation in AML pathogenesis)汇报者及单位：Hui Feng，西安交通大学第一附属医院02摘要号：S125英文标题：CELL-INTRINSIC INFLAMMATION SHAPES CELL-STATE HETEROGENEITY AND DRIVES THERAPEUTIC RESISTANCE IN HUMAN ACUTE MYELOID LEUKEMIA中文标题：细胞内在炎症塑造人类急性髓系白血病细胞状态异质性并驱动治疗耐药性类型：口头报告专场名称：AML免疫治疗的新进展（Novel advances in AML immunotherapy）汇报者及单位：Lina Liu，浙江大学医学院附属第一医院骨髓移植中心急性髓系白血病——临床Acute myeloid leukemia - Clinical01摘要号：S143英文标题：LONG-TERM FOLLOW-UP OF PREDOMINANTLY ASIAN PATIENTS WITH RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY IN THE PHASE 3 COMMODORE TRIAL中文标题：Ⅲ期COMMODRE试验中接受吉瑞替尼与挽救化疗治疗的复发/难治性FLT3突变急性髓系白血病患者（以亚洲患者为主）的长期随访类型：口头报告专场名称：AML的新疗法与FLT3抑制剂（Novel therapies and FLT3 inhibition for AML）汇报者及单位：王建祥，中国医学科学院血液病医院（中国医学科学院血液学研究所）侵袭性非霍奇金淋巴瘤——临床Aggressive Non-Hodgkin lymphoma - Clinical01摘要号：S246英文标题：A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL)中文标题：SHR2554[一种口服的增强子同源物2（EZH2）抑制剂）]用于复发或难治性（R/R）外周T细胞淋巴瘤（PTCL）的治疗：一项关键研究类型：口头报告专场名称：侵袭性非霍奇金淋巴瘤——临床（前瞻性）[Aggressive Non-Hodgkin lymphoma - Clinical (Prospective)]汇报者及单位：宋玉琴，北京大学肿瘤医院出血性疾病（先天性和获得性）Bleeding disorders (congenital and acquired)01摘要号：S315英文标题：BLASTS- AND MODIFIED EASIX-GUIDED RISK STRATIFICATION FOR CAR-T-ASSOCIATED COAGULOPATHY AND OUTCOMES中文标题：BLASTS和改良EASIX指导的CAR-T相关凝血病及预后的风险分层类型：口头报告专场名称：出血性疾病（先天性和获得性）[Bleeding disorders (congenital and acquired)]汇报者及单位：Yingying Li，华中科技大学同济医学院附属协和医院骨髓衰竭综合征（包括PNH）——临床Bone marrow failure syndromes incl.PNH-Clinical01摘要号：S184英文标题：EFFICACY AND SAFETY OF CYCLOSPORINE PLUS LUSPATERCEPT VERSUS CYCLOSPORINE IN NEWLY DIAGNOSED NON-TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE RANDOMIZED TRIAL中文标题：环孢素联合罗特西普 vs. 环孢素治疗新诊断非输血依赖型非重型再生障碍性贫血的疗效和安全性：一项前瞻性随机试验类型：口头报告专场名称：骨髓衰竭综合征(Bone marrow failure syndromes)汇报者及单位：Zhuxin Zhang，中国医学科学院北京协和医院慢性髓系白血病——生物学及转化研究Chronic myeloid leukemia-Biology & translational research01摘要号：S162英文标题：INTEGRATING GENOMIC AND TRANSCRIPTOMIC INSIGHTS FOR PREDICTING RESPONSES AND OUTCOMES IN PATIENTS WITH CML RECEIVING 3RD-GENERATION TKI THERAPY中文标题：整合基因组与转录组见解以预测接受第三代TKI治疗的CML患者的反应和预后类型：口头报告专场名称：CML治疗反应与耐药的生物学(Biology of CML treatment response and resistance)汇报者及单位：张小帅，北京大学人民医院基因治疗、细胞免疫治疗和疫苗接种——生物学和转化研究Gene therapy,cellular immunotherapy and vaccination-Biology & translational research01摘要号：S277英文标题：TYPE I INTERFERON IMPAIRS CAR-T CELL FUNCTION BY DISRUPTING IMMUNE SYNAPSE ASSEMBLY中文标题：I型干扰素通过破坏免疫突触组装削弱CAR-T细胞功能类型：口头报告专场名称：基因治疗、细胞免疫治疗和疫苗接种——生物学和转化研究（Gene therapy, cellular immunotherapy and vaccination - Biology & translational research）汇报者及单位：Meijuan Huang，华中科技大学同济医学院附属同济医院基因治疗、细胞免疫治疗和疫苗接种——临床Gene therapy,cellular immunotherapy and vaccination-Clinical01摘要号：S283英文标题：CTD402: A UNIVERSAL ANTI-CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY (R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)中文标题：CTD402：一种针对复发或难治性（R/R）T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤（T-ALL/LBL）患者的通用抗CD7嵌合抗原受体T细胞疗法类型：口头报告专场名称：基因治疗、细胞免疫治疗和疫苗接种——临床（Gene therapy, cellular immunotherapy and vaccination - Clinical）汇报者及单位：Jiangtao Ren，Bioheng Therapeutics Co., Ltd,, Nanjing, China造血、干细胞和微环境Hematopoiesis,stem cells and microenvironment01摘要号：S272英文标题：ENHANCE THE THERAPEUTIC EFFICACY OF HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS IN PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH CRISPLD2 MODULATION中文标题：通过调控CRISPLD2增强人脐带间充质干细胞在预防急性移植物抗宿主病中的治疗效果类型：口头报告专场名称：造血干细胞及其微环境(Hematopoietic stem cells and their niche)汇报者及单位：Xu Qing，陆军军医大学第二附属医院（新桥医院）02摘要号：S273英文标题：TGF-ß1-TRIGGERED MALADAPTIVE BONE MARROW ENDOTHELIUM IMPEDES HEMATOPOIETIC RECOVERY中文标题：TGF-β1诱导的骨髓内皮功能失调阻碍造血恢复类型：口头报告专场名称：造血干细胞及其微环境(Hematopoietic stem cells and their niche)汇报者及单位：Zhong-Shi Lyu，北京大学人民医院淋巴瘤生物学与转化研究Lymphoma biology & translational research01摘要号：S251英文标题：MULTI-OMICS DISSECTION OF EBV-DRIVEN HETEROGENEITY, METABOLIC REMODELING, AND TUMOR CELLULAR LANDSCAPE IN ENKTL PROGRESSION中文标题：EB病毒驱动的ENKTL进展中的异质性、代谢重塑及肿瘤细胞图谱的多组学解析类型：口头报告专场名称：淋巴瘤生物学与转化研究(Lymphoma biology & translational research)汇报者及单位：梁金花，南京医科大学第一附属医院（江苏省人民医院）02摘要号：S252英文标题：PTPN2 INHIBITION DISRUPTS MITOCHONDRIAL RENEWAL AND BLOCKS TFRC-MEDIATED PINK1-PRKN-DEPENDENT MITOPHAGY TO EXERT ANTI-TUMOR ACTIVITIES IN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA中文标题：PTPN2抑制通过破坏线粒体更新并阻断TFRC介导的PINK1-PRKN依赖性线粒体自噬，在ALK阳性间变性大细胞淋巴瘤中发挥抗肿瘤作用类型：口头报告专场名称：淋巴瘤生物学与转化研究(Lymphoma biology & translational research)汇报者及单位：梁金花，南京医科大学第一附属医院（江苏省人民医院）骨髓增生异常综合征——生物学与转化研究Myelodysplastic syndromes-Biology & translational research01摘要号：S170英文标题：SINGLE-CELL ATLAS OF PEDIATRIC NRAS-MUTANT MYELOID NEOPLASMS REVEALS MYELOID LINEAGE BIAS AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS中文标题：儿童NRAS突变髓系肿瘤的单细胞图谱揭示髓系谱系偏倚并识别潜在治疗靶点类型：口头报告专场名称：MDS cellular and molecular therapeutic targeting汇报者及单位：Suyu Zong，中国医学科学院血液病医院（中国医学科学院血液学研究所）骨髓瘤及其他单克隆免疫球蛋白病——生物学与转化研究Myeloma and other monoclonal gammopathies -Biology & translational research01摘要号：S188英文标题：ENHANCER EXTRACHROMOSOMAL CIRCULAR DNA ANKRD28 DRIVES DRUG RESISTANCE VIA POU2F2-MEDIATED TRANSCRIPTIONAL REWIRING IN MULTIPLE MYELOMA中文标题：增强子染色体外环状DNA ANKRD28通过POU2F2介导的转录重编程驱动多发性骨髓瘤的药物耐药类型：口头报告专场名称：骨髓瘤及其他单克隆免疫球蛋白病——生物学与转化研究（Myeloma and other monoclonal gammopathies - Biology & translational research）汇报者及单位：Binzhen Chen，上海交通大学医学院附属仁济医院骨髓增生性肿瘤——临床Myeloproliferative neoplasms-Clinical01摘要号：S222英文标题：ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-RISK MYELOFIBROSIS中文标题：罗培干扰素α-2b治疗纤维化前原发性骨髓纤维化及DIPSS低/中风险骨髓纤维化类型：口头报告专场名称：Innovative treatment approaches in MPN汇报者及单位：Harry Gill，中国香港大学李嘉诚医学院血液学中的新技术、新方法及数字分析工具Novel technologies,techniques and digital analytical tools in hematology01摘要号：S332英文标题：STEM CELL AGING CLOCK: A DEEP LEARNING DRIVEN FRAMEWORK FOR PREDICTING STEM CELL AGE中文标题：干细胞衰老时钟：基于深度学习的干细胞年龄预测框架类型：口头报告专场名称：计算机与人工智能辅助血液学的新进展（New developments in computational and AI-assisted hematology）汇报者及单位：Guanlin Wang，复旦大学代谢与整合生物学研究院血小板疾病Platelet disorders01摘要号：S313英文标题：BARICITINIB CORRECTS AP2-NAK MEDIATED C-MPL ENDOCYTIC DYSREGULATION TO RESTORE MEGAKARYOCYTES TPO-RA SENSITIVITY IN IMMUNE THROMBOCYTOPENIA中文标题：巴瑞替尼纠正AP2-NAK介导的c-MPL内吞调控异常，恢复免疫性血小板减少症中巨核细胞对TPO-RA的敏感性类型：口头报告专场名称：血小板疾病（Platelet disorders）汇报者及单位：安倬玉，北京大学人民医院02摘要号：S318英文标题：TARGETED SUPPRESSION OF EFFECTOR T CELLS BY GPIBα CAAR-TREG CELLS IN REFRACTORY/RELAPSED IMMUNE THROMBOCYTOPENIA中文标题：GPIBα CAAR-Treg细胞对难治/复发性免疫性血小板减少症效应T细胞的靶向抑制类型：口头报告专场名称：出血性疾病（先天性与获得性）[Bleeding disorders (congenital and acquired)]汇报者及单位：Jinhui Shu，华中科技大学同济医学院附属协和医院干细胞移植——临床Stem cell transplantation-Clinical01摘要号：S261英文标题：AUTONOMOUS AI-DRIVEN INTENSIFIED PROPHYLAXIS OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL TRANSPLANTS: A SINGLE-CENTRE, PROOF-OF-CONCEPT, PHASE 2 TRIAL中文标题：自主人工智能驱动的加强预防严重急性移植物抗宿主病在半相合移植中的应用：一项单中心概念验证Ⅱ期试验类型：口头报告专场名称：干细胞移植——专场2(Stem cell transplantation - Session 2)汇报者及单位：Yigeng Cao，中国医学科学院血液病医院（中国医学科学院血液学研究所）02摘要号：S262英文标题：ANTI-CD25 ANTIBODY AS AN ALTERNATIVE TO METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS RESULTED IN BETTER OUTCOMES IN PATIENT OF CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY BRIDGING TO TRANSPLANT中文标题：抗CD25抗体作为替代甲氨蝶呤的移植物抗宿主病预防方案，在嵌合抗原受体T细胞治疗桥接移植患者中取得了更好的疗效类型：口头报告专场名称：干细胞移植——专场2（Stem cell transplantation - Session 2）汇报者及单位：李智慧，北京高博博仁医院03摘要号：S263英文标题：PHARMACOKINETIC-GUIDED ATG DOSING OPTIMIZES OUTCOMES IN MYELOABLATIVE HAPLO-CORD HCT中文标题：基于药代动力学指导的ATG给药优化改善了清髓性半相合脐带血干细胞移植的治疗效果类型：口头报告专场名称：干细胞移植——专场2（Stem cell transplantation - Session 2）汇报者及单位：Qingya cui,苏州大学附属第一医院04摘要号：S256英文标题：TARGETED DOSING OF ANTI-THYMOCYTE GLOBULIN VERSUS FIXED DOSING STRATEGY IN PATIENTS UNDERGOING UNMANIPULATED HAPLOIDENTICAL HAEMATOPOIETIC STEM-CELL TRANSPLANTATION: A RANDOMIZED, MULTICENTER, PHASE 3 CLINICAL TRIAL中文标题：抗胸腺细胞球蛋白的目标给药与固定给药策略在接受未处理半相合造血干细胞移植患者中的比较：一项随机、多中心、Ⅲ期临床试验类型：口头报告专场名称：干细胞移植——专场1（Stem cell transplantation - Session 1）汇报者及单位：刘代红，解放军总医院第五医学中心05摘要号：S258英文标题：WHO IS THE BEST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONOR FOR SEVERE APLASTIC ANEMIA? A MULTICENTER RETROSPECTIVE EXPERIENCE FROM CHINA中文标题：重型再生障碍性贫血的最佳异基因造血干细胞移植供者是谁？来自中国的多中心回顾性研究经验类型：口头报告专场名称：干细胞移植——专场1（Stem cell transplantation - Session 1）汇报者及单位：Xiao-Di Ma，北京大学人民医院06摘要号：S259英文标题：COMPARABLE SURVIVAL OUTCOMES IN HLA-MATCHED AND HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS AGED 40-50: A CBMTR REGISTRY-BASED PSM ANALYSIS OVER THE LAST DECADE中文标题：接受HLA匹配与半相合造血干细胞移植40-50岁重型再生障碍性贫血患者的生存结局相当：过去十年基于CBMTR登记的PSM分析类型：口头报告专场名称：干细胞移植——专场1（Stem cell transplantation - Session 1）汇报者及单位：许兰平，北京大学人民医院干细胞移植——实验Stem cell transplantation-Experimental01摘要号：S255英文标题：JAK/ROCK INHIBITION WITH ROVADICITINIB SUPPRESSES MURINE AND HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE: THE RESULTS OF PRECLINICAL AND PHASE 1B STUDY中文标题：JAK/ROCK抑制剂罗伐昔替尼抑制小鼠及人类急性移植物抗宿主病：临床前及Ⅰb期研究结果类型：口头报告专场名称：干细胞移植——专场1（Stem cell transplantation - Session 1）汇报者及单位：赵妍敏，浙江大学医学院附属第一医院骨髓移植中心地中海贫血Thalassemias01摘要号：S290英文标题：EFFICACY AND SAFETY OF BRL-101 IN TDT AND SCD中文标题：BRL-101 在输血依赖型地中海贫血（TDT）和镰状细胞病（SCD）中的疗效与安全性类型：口头报告专场名称：地中海贫血和红细胞生成（Thalassemia and erythopoiesis）汇报者及单位：Tan Qian，Shanghai tech immunology department, Shanghai, China02摘要号：S291英文标题：TREATMENT OF PATIENTS WITH SEVERE TRANSFUSION-DEPENDENT ß-THALASSEMIA WITH CS-101, AN AUTOLOGOUS, EX VIVO EDITED, CD34+ HEMATOPOIETIC STEM CELL PRODUCT USING INNOVATIVE TRANSFORMER BASE EDITOR (TBE)中文标题：采用创新型Transformer基础编辑器（TBE）对自体CD34+造血干细胞进行体外编辑制备的CS-101，用于治疗重型输血依赖型β-地中海贫血患者类型：口头报告专场名称：地中海贫血和红细胞生成（Thalassemia and erythopoiesis）汇报者及单位：陈佳，上海科技大学生命科学与技术学院基因编辑中心03摘要号：S292英文标题：FIRST-IN-HUMAN STUDY OF AUTOLOGOUS HBA2-EDITED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS IN ALPHA-THALASSEMIA WITH CONSTANT SPRING MUTATION中文标题：首次人体研究：自体HBA2基因编辑的CD34+造血干/祖细胞用于Constant Spring突变型α-地中海贫血治疗类型：口头报告专场名称：地中海贫血和红细胞生成（Thalassemia and erythopoiesis）汇报者及单位：Hui Xu，Reforgene Medicine, Guangzhou, China（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

蛋白降解靶向嵌合体临床结果

100 项与 Zeprumetostat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外周T细胞淋巴瘤	申请上市	中国	江苏恒瑞医药股份有限公司	2024-10-11
晚期前列腺癌	临床2期	中国	江苏恒瑞医药股份有限公司	2024-09-06
滤泡性淋巴瘤	临床2期	中国	江苏恒瑞医药股份有限公司	2024-04-01
难治性滤泡性淋巴瘤	临床2期	中国	江苏恒瑞医药股份有限公司	2024-04-01
难治性经典霍奇金淋巴瘤	临床2期	中国	中国人民解放军总医院	2023-06-14
去势抵抗性前列腺癌	临床2期	美国	Treeline Biosciences, Inc.	2023-02-12
晚期恶性实体瘤	临床2期	中国	中国人民解放军总医院	2020-09-01
B细胞淋巴瘤	临床2期	中国	中国人民解放军总医院	2020-09-01
转移性去势抵抗性前列腺癌	临床2期	中国	江苏恒瑞医药股份有限公司	2018-11-20
典型霍奇金淋巴瘤	临床1期	中国	苏州大学附属第一医院	2022-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03603951 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	外周T细胞淋巴瘤	28	SHR2554 350 mg twice daily	築壓醖鬱衊衊壓鹽襯鬱(憲糧衊鬱範範襯壓願獵) = 糧願窪範網齋遞鑰積憲獵製淵醖鬱築壓願醖築 (顧憲製網獵製鹹鬱網艱, 41 ~ 78) 更多	积极	2024-04-01
NCT04407741 (ASCO2023) 人工标引	临床1期	实体瘤 \| 晚期淋巴瘤	32	SHR-1701 + SHR2554	廠淵築糧糧蓋襯衊醖獵(選積顧窪觸範遞廠壓艱) = SHR2554 350mg bid plus SHR-1701 30mg/kg q3w 獵襯壓夢窪積鬱淵淵蓋 (簾鏇衊簾鑰鏇鏇構範窪 ) 更多	积极	2023-05-31
NCT03603951 (Pubmed \| Lancet Haematol) 人工标引	临床1期	淋巴瘤	113	SHR 2554	齋壓衊製簾餘艱憲蓋夢(鹹淵鹽願獵淵鹹膚膚壓) = 繭廠獵繭網艱膚糧觸壓簾壓觸艱膚顧窪艱鏇構 (蓋鹹顧鏇餘顧願獵蓋鬱 ) 更多	积极	2022-07-01
NCT03603951 (ASCO2022)	临床1期	淋巴样瘤	113	SHR2554	膚壓遞製膚鑰夢選選餘(夢淵艱積齋鹹選膚構願) = 網齋糧構顧壓廠膚範齋襯鏇廠範獵簾觸廠鑰襯 (壓範鹹糧窪鑰願鏇壓製, 42.1 ~ 73.7) 更多	-	2022-06-02